Biotech · Public company · New York, NY, US
Siga Technologies Inc
Ticker SIGA · SEC CIK 0001010086
Track this companyFree. Adds Siga Technologies Inc to your Dealase workspace and tells you when its record changes.
Clinical trials91 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline13
- tecovirimatPhase 3 · SmallpoxClinicalTrials.gov · fetched Nov 12, 2026
- TPOXXPhase 3 · SmallpoxClinicalTrials.gov · fetched Nov 12, 2026
- Smallpox and Mpox VaccinePhase 2 · SmallpoxClinicalTrials.gov · fetched Nov 12, 2026
- ST-246 400 mgPhase 2 · Orthopoxviral DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ST-246 600 mgPhase 2 · Orthopoxviral DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ST-246Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- ST-246 Days 1 - 3Phase 1 · Orthopoxviral DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ST-246 Days 11 - 13Phase 1 · Orthopoxviral DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- calcium acetate oral tabletSmallpoxClinicalTrials.gov · fetched Nov 12, 2026
- Lanthanum Carbonate Chewable TabletSmallpoxClinicalTrials.gov · fetched Nov 12, 2026
- sevelamer carbonate oral tabletSmallpoxClinicalTrials.gov · fetched Nov 12, 2026
- sucroferric oxyhydroxide chewable tabletSmallpoxClinicalTrials.gov · fetched Nov 12, 2026
- TPOXX 200Mg CapsuleSmallpoxClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate BindersPHASE4 · COMPLETED · started Jun 8, 2022ClinicalTrials.gov NCT04485039 · fetched Nov 12, 2026
- Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 5, 2022ClinicalTrials.gov NCT04957485 · fetched Nov 12, 2026
- Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysPHASE3 · COMPLETED · started Mar 29, 2022ClinicalTrials.gov NCT04971109 · fetched Nov 12, 2026
- A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With SmallpoxWITHDRAWN · started Jan 1, 2020ClinicalTrials.gov NCT03972111 · fetched Nov 12, 2026
- Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KGPHASE4 · COMPLETED · started Jul 19, 2019ClinicalTrials.gov NCT04392739 · fetched Nov 12, 2026
- A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatPHASE3 · COMPLETED · started Jun 19, 2015ClinicalTrials.gov NCT02474589 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246PHASE2 · COMPLETED · started Jun 1, 2009ClinicalTrials.gov NCT00907803 · fetched Nov 12, 2026
- Phase I Trial of an Investigational Small Pox MedicationPHASE1 · COMPLETED · started Aug 1, 2008ClinicalTrials.gov NCT00728689 · fetched Nov 12, 2026
- Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy VolunteersPHASE1 · COMPLETED · started Feb 1, 2007ClinicalTrials.gov NCT00431951 · fetched Nov 12, 2026
SEC filings12
- 10-Q · FORM 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 10, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 26, 2026 · fetched Nov 12, 2026
- 10-K · FORM 10-KSEC EDGAR · filed Mar 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 10, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Nov 6, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 6, 2025 · fetched Nov 12, 2026